Hospital
Bellevue Medical Center LLC
Bellevue Medical Center LLC was paid $7.18M by Medicaid between Jan 2018 and Dec 2024, across 147 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoBELLEVUE MEDICAL CENTER LLC
BELLEVUE, NE 68123
BELLEVUE, NE 68123
33aNPI1609007525assigned 07/28/2009
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.18M
24GClaims224,150
24DCodes billed147
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nebraska
Rank by total paid#3 of 8
Median peer was paid$1.62M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,468 | $865K | |
| 2019 | 27,776 | $760K | |
| 2020 | 23,472 | $822K | |
| 2021 | 48,738 | $1.42M | |
| 2022 | 61,301 | $2.00M | |
| 2023 | 24,442 | $947K | |
| 2024incomplete | 6,953 | $364K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 13,656 | 12,543 | $1.60M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 4,261 | 3,611 | $988K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 7,528 | 7,007 | $732K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 8.7% | 2,238 | 2,084 | $628K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.0% | 1,680 | 1,556 | $431K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.3% | 3,715 | 3,547 | $379K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 3,163 | 2,879 | $340K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.5% | 1,702 | 1,540 | $324K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.1% | 4,353 | 1,445 | $296K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.5% | 550 | 505 | $107K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 867 | 800 | $88K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,408 | 2,253 | $71K |
135 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 807 | $69K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 292 | $66K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 824 | $62K |
| 80053 | Comprehensive metabolic panel | <1% | 16,247 | $59K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 700 | $51K |
| J3490 | Unclassified drugs | <1% | 12,319 | $43K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,199 | $42K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,793 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,518 | $39K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 174 | $37K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,844 | $36K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 210 | $35K |
| G0378 | Hospital observation service, per hour | <1% | 780 | $33K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,338 | $32K |
| 93976 | <1% | 319 | $27K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,206 | $24K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 698 | $24K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,426 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 886 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,590 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,599 | $20K |
| C8957 | Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump | <1% | 122 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 886 | $18K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 17 | $15K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,031 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,960 | $14K |
| 97165 | <1% | 204 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,925 | $12K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,295 | $11K |
| 80061 | Lipid panel | <1% | 1,547 | $11K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 359 | $10K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 24 | $10K |
| 81025 | <1% | 3,504 | $10K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 186 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,693 | $8K |
| 73562 | <1% | 403 | $8K | |
| 94761 | <1% | 797 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,678 | $8K |
| 85027 | <1% | 2,024 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 771 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,949 | $7K |
| 87081 | <1% | 1,200 | $7K | |
| 83690 | <1% | 2,908 | $7K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 60 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,889 | $7K |
| 83735 | <1% | 2,956 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 369 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,060 | $6K |
| 84484 | <1% | 3,286 | $6K | |
| 12001 | <1% | 24 | $6K | |
| 73630 | <1% | 242 | $6K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 10,619 | $6K |
| 82805 | <1% | 115 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,986 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 261 | $5K |
| 73610 | <1% | 243 | $5K | |
| 84439 | <1% | 591 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,708 | $5K |
| 87631 | <1% | 29 | $4K | |
| 81001 | <1% | 3,510 | $4K | |
| 83605 | <1% | 1,621 | $4K | |
| A9270 | Non-covered item or service | <1% | 6,548 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,612 | $4K |
| 97161 | <1% | 188 | $3K | |
| 81003 | <1% | 3,728 | $3K | |
| 83880 | <1% | 651 | $3K | |
| 96376 | <1% | 713 | $2K | |
| 97162 | <1% | 184 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 164 | $2K |
| 85610 | <1% | 1,354 | $2K | |
| 72100 | <1% | 54 | $2K | |
| 85379 | <1% | 1,048 | $2K | |
| 85007 | <1% | 541 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 141 | $1K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 240 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 631 | $1K |
| 84145 | <1% | 793 | $1K | |
| 84100 | <1% | 992 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $1K |
| 73130 | <1% | 24 | $1K | |
| 73110 | <1% | 48 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 721 | $943.07 |
| 84703 | <1% | 139 | $938.76 | |
| 86140 | <1% | 624 | $911.40 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 434 | $910.65 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 62 | $854.51 |
| 84702 | <1% | 64 | $847.38 | |
| 73030 | <1% | 89 | $843.63 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 55 | $842.31 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $779.66 |
| 82570 | <1% | 225 | $723.99 | |
| 82728 | <1% | 80 | $717.53 | |
| 84466 | <1% | 118 | $649.87 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 581 | $558.93 |
| 87077 | <1% | 219 | $554.64 | |
| 73502 | <1% | 29 | $552.68 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 917 | $511.66 |
| 82607 | <1% | 42 | $506.35 | |
| 83540 | <1% | 137 | $470.14 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 233 | $441.10 |
| 82550 | <1% | 94 | $411.23 | |
| 76830 | Ultrasound, transvaginal | <1% | 89 | $324.30 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 74 | $321.74 |
| 87210 | <1% | 66 | $319.31 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 1,495 | $294.50 |
| 86900 | <1% | 47 | $293.22 | |
| 87807 | <1% | 17 | $226.44 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 28 | $194.70 |
| 87186 | <1% | 122 | $175.63 | |
| 85652 | <1% | 120 | $142.66 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 238 | $127.33 |
| 85730 | <1% | 254 | $124.20 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,630 | $89.48 |
| 82043 | <1% | 30 | $77.58 | |
| 86901 | <1% | 35 | $69.42 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 369 | $64.65 |
| 80179 | <1% | 306 | $37.28 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 90 | $26.67 |
| 80143 | <1% | 313 | $18.64 | |
| 87040 | <1% | 94 | $16.89 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 82 | $10.19 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 179 | $8.19 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,046 | $3.86 |
| 85014 | <1% | 24 | $3.38 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 36 | $0.00 |
| 94664 | 0% | 30 | $0.00 | |
| J7070 | Infusion, d5w, 1000 cc | 0% | 17 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 20 | $0.00 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 15 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 159 | $0.00 |
| 99156 | 0% | 13 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 340 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 119 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 96 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 73 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAUBERT, STEPHANIE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Nebraska Medical Center | Omaha, NE | $76.40M |
| Unmc Physicians | Omaha, NE | $41.01M |
| Nebraska Medical Center | Omaha, NE | $62K |
| Nebraska Medical Center | Omaha, NE | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.